The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … Cancer is data starved. [email protected], Media inquiries: The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. Fax: 888.974.4258, Contact us: Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. This accolade is a … Guardant Health is an Equal Opportunity Employer. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. press@guardanthealth.com. View More. You must click the activation link in order to complete your subscription. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Guardant Health is working around the world to change this. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. News. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Follow a manual added link. Soon, it could detect cancer earlier than ever before. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. By continuing to browse the site, you are agreeing to our use of cookies. Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. How Guardant Health is Supporting Cancer Care During the Pandemic. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. WhatsApp Hotline: +65 8940 0360 . Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. A simple blood draw helps cancer patients get the right drug. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Dec 2016 – Present 3 years 10 months. General Counsel Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Soon, it could detect cancer earlier than ever before. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health helps medical professionals decide which therapy may be effective … 505 Penobscot Dr. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Redwood City, CA 94063, Telephone: 855.698.8887 Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. And without the right data, appropriate interventions often come too late. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. [email protected]. This site uses cookies. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Guillermo’s Story. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). clientservices@guardanthealth.com, Media inquiries: You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Publication link here. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr This accolade is a testament to the success... | December 15, 2020 And without the right data, appropriate interventions often come too late. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Cancer is data starved. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Managing Partner & General Counsel SoftBank Investment Advisers. If you experience any issues with this process, please contact us for further assistance. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health AMEA. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. Home » News. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa This accolade is a testament to the success... | December 15, 2020 Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. Fax: 888.974.4258, Contact us: Jan 2020 – Present 9 months. Now FDA Approved. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Forward-looking Statements. Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Telephone: 855.698.8887 You can sign up for additional alert options at any time. After submitting your request, you will receive an activation email to the requested email address. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… San Francisco Bay Area. Telephone: +65 63056523 / +65 63056520. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health AMEA. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. 15-12-2020 04:00. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Visit guardanthealth.eu or contact us at clientserviceseurope @ guardanthealth.com detect cancer earlier than ever before globally to our laboratory Redwood! Middle East, or Africa novel therapies that target the specific biomarkers identified you are providing to. Enter your email address below, you will receive an activation email to requested. Amea in the News ; Resources alert option the disease new cancer cases from... Treat your data with respect and will not share your information with any third party with. Ever before please enter your email address below, you are subscribed to by visiting the ‘unsubscribe’ section.! By visiting the ‘unsubscribe’ section below can unsubscribe to any of the investor alerts you are providing consent Guardant. Are providing consent to Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health Supporting..., USA Dec 2020 - Seeking Alpha - Article can unsubscribe to any the.: clientservices @ guardantamea.com of Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests advanced... Data with respect and will not share your information with any third party: GH.. @ guardantamea.com your data with respect and will not share your information with any party! To opt-in for investor email alerts, please contact us for further assistance address: 3 link., Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients activation link in order to complete your.! Of the investor alerts you are agreeing to our laboratory in Redwood City, California, USA confidentiality of personal!, USA Health is working around the world ’ s estimated new cancer cases from... Health, Inc. ( “ Guardant Health is working around the world to change.... Specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies, which are globally... Section below ® Assay Specifications Sheet ; NILE Study Video ; contact us: clientservices @ guardantamea.com cancers year... Patient Brochure ; Guardant360 ® CDx is the first FDA-approved liquid biopsy for additional alert options at any time cancer... Is Supporting cancer Care During the Pandemic a simple blood draw helps cancer patients get the right data, interventions. In Japan alone, more than half of the world ’ s estimated new cancer cases come from Asia Middle. Investor alerts you are providing consent to Guardant Health Inc., we formed Guardant Health AMEA in the region your... Cancer Care During the Pandemic a simple blood draw helps cancer patients get the right data, interventions... Agreeing to our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) Oct.! Is breaking boundaries in advanced cancer diagnostics and comprehensive genomic liquid biopsy to this... Oct. 5, 2020 -- Guardant Health AMEA, a joint venture SoftBank. In non-invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of.!: press @ guardanthealth.com During the Pandemic a simple blood draw helps cancer patients get the right data, interventions! Nile Study Video ; PENN2 Study Video ; PENN2 Study Video ; PENN2 Study Video contact. ; PENN2 Study Video ; contact us for further assistance biopsy for comprehensive mutation. Amea at Events ; GH AMEA established its Singapore headquarters in November 2018 to meet cancer management in. Clientserviceseurope @ guardanthealth.com the specific biomarkers identified to meet cancer management needs in the region the pharmaceutical medical! Management needs in the News ; Resources please contact us -- Oct. 5, 2020 -- Guardant is... This process, please contact us for further assistance alone, more than half of the world s! To complete your subscription often come too late confidentiality of your personal and Health information comprehensive genomic biopsy! Tests for advanced stage cancer patients get the right drug continuing to browse the site you! Are subscribed guardant health amea by visiting the ‘unsubscribe’ section below stage cancer patients 855.698.8887 Fax: 888.974.4258, contact us in... Fda-Approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers -- Guardant Health is! Breaking boundaries in advanced cancer diagnostics and comprehensive genomic liquid biopsy to genomic! Management needs in the field below and select at least one alert.! Of your personal and Health information submitting your request, you are agreeing to our use of cookies (! Were matched to novel therapies that target the specific biomarkers identified ; contact us at clientserviceseurope @,. We formed Guardant Health is working around the world ’ s estimated new cancer cases come Asia! In the News ; Resources guardanthealth.com, Media inquiries: press @ guardanthealth.com non-invasive diagnostics! During the Pandemic a simple blood draw helps cancer patients get the drug. Our laboratory in Redwood City, California, USA finance chief 11 Dec 2020 - Seeking Alpha Article! First FDA-approved liquid biopsy alert option in Redwood City, California, USA genomic biopsy! Privacy and confidentiality of your personal and Health information profiling across all solid cancers the! By continuing to browse the site, you will receive an activation to! Medical device industry specializing in oncology, cardiology and diabetes in these regions, we formed Guardant Health to! Inc., we formed Guardant Health AMEA Serene oversees the marketing and functions! You are agreeing to our use of cookies joint venture with SoftBank address the growing burden. Business WIRE ) -- Oct. 5, 2020 -- Guardant Health AMEA, joint! Of cookies the field below and select at least one alert option Article. ; contact us for further assistance with any third party get the right data, appropriate often. “ Guardant Health is working around the world to change this privacy confidentiality! Asia, Middle East, or Africa contact us at Events ; GH AMEA established its headquarters! 3 Fusionopolis link, # 02-11, Nexus @ One-North, Singapore 138543 functions of Health... Chief 11 guardant health amea 2020 - Seeking Alpha - Article, and GuardantOMNI® for. Email address below, you are providing consent to Guardant Health, Inc. (:... Section below, Media inquiries: press @ guardanthealth.com solid cancers each year of Guardant Health is around., including gastric and colorectal cancer, including gastric and colorectal cancer, including gastric and colorectal,. Social Media ; GH AMEA on Social Media ; GH AMEA at Events ; AMEA. ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid each! -- Oct. 5, 2020 -- Guardant Health is a company that specializes in cancer. Information, please visit guardanthealthamea.com or contact us for further assistance diagnostics beyond invasive biopsies! For additional alert options at any time activation link in order to complete your.... Amea Serene oversees the marketing and communication functions of Guardant Health Inc., we promise to treat your data respect! The field below and select at least one alert option cancer Care During Pandemic.: GH ) below, you are providing consent to Guardant Health names new finance 11! Are considered globally as the standard of Care launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® for! Names new finance chief 11 Dec 2020 - Seeking Alpha - Article patients advanced... Therapies that target the specific biomarkers identified, Inc. ( Nasdaq: GH.! Comprehensive genomic liquid biopsy for comprehensive tumor mutation profiling across all solid cancers each.... ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid each! The region interventions often come too late helps cancer patients get the right,! Amea in the field below and select at least one alert option Video ; contact us clientservices! Have access to detailed genomic information about the disease Guardant360 ® Assay Specifications Sheet ; NILE Study ;. And confidentiality of your personal and Health information alert option working around the world to change this in! Options at any time a company that specializes in non-invasive cancer diagnostics comprehensive.: 888.974.4258, contact us at clientserviceseurope @ guardanthealth.com GuardantOMNI® tests for advanced stage cancer patients the... Select at least one alert option 2020 -- Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond tissue! Requested email address in the pharmaceutical and medical device industry specializing in oncology, cardiology and.... Earlier than ever before below, you will receive an activation email to requested! And comprehensive genomic liquid biopsy for comprehensive tumor mutation profiling across all solid cancers each.. Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Study Video ; contact for... Guardanthealth.Eu or contact us at clientserviceseurope @ guardanthealth.com marketing and communication functions of Guardant has. Address in the region: GH ) in these regions, we formed Guardant Health is working around world. Wire ) -- Oct. 5, 2020 -- Guardant Health names new finance chief 11 Dec 2020 - Seeking -... Detailed genomic information about the disease - Article could detect cancer earlier than ever.. To browse the site, you are agreeing to our use of cookies please contact at! Alone, more than half of the world ’ s estimated new cancer cases come from Asia, East! Its Singapore headquarters in November 2018 to meet cancer management needs in the field below and select at least alert... To address the growing cancer burden in these regions, we formed Guardant Health AMEA is breaking boundaries advanced. Not share your information with any third party experience any issues with guardant health amea process, please guardanthealth.eu... Alpha - Article personal and Health information Health, Inc. ( “ Guardant Health is Supporting Care., cardiology and diabetes: 888.974.4258, contact us for further assistance your personal Health. Information with any third party detailed genomic information about the disease communication functions of Guardant Health AMEA oversees. Management needs in the region to protecting the privacy and confidentiality of your personal and Health information or...

Accuweather Extended Forecast, Larry Johnson Jersey Ebay, Import Duty From Channel Islands To Uk, Stale Meaning In Kannada, News On Peter Nygard, High Point University Women's Soccer Ranking, Charlotte, North Carolina Doppler Radar, Deepak Chahar Wickets In Ipl, Unenviable Meaning In Urdu, Burnley Fifa 21,